Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella.
BACKGROUND
Resistance to most or all cephalosporin antibiotics in Klebsiella species has developed in many European and North American hospitals during the past 2 decades.


OBJECTIVE
To determine if restriction of use of the cephalosporin class of antibiotics would reduce the incidence of patient infection or colonization by cephalosporin-resistant Klebsiella.


METHODS
A before-after comparative 2-year trial.


METHODS
A 500-bed, university-affiliated community hospital in Queens, NY.


METHODS
All adult medical and surgical hospital inpatients.


METHODS
A new antibiotic guideline excluded the use of cephalosporins except for pediatric infection, single-dose surgical prophylaxis, acute bacterial meningitis, spontaneous bacterial peritonitis, and outpatient gonococcal infection. All other cephalosporin use required prior approval by the infectious disease section.


METHODS
Incidence of patient infection or colonization by ceftazidime-resistant Klebsiella during 1995 (control period) compared with 1996 (intervention period).


RESULTS
An 80.1% reduction in hospital-wide cephalosporin use occurred in 1996 compared with 1995. This was accompanied by a 44.0% reduction in the incidence of ceftazidime-resistant Klebsiella infection and colonization throughout the medical center (P<.01), a 70.9% reduction within all intensive care units (P<.001), and an 87.5% reduction within the surgical intensive care unit (P<.001). A concomitant 68.7% increase in the incidence of imipenem-resistant Pseudomonas aeruginosa occurred throughout the medical center (P<.01). All such isolates except one were susceptible to other antibiotics.


CONCLUSIONS
Extensive cephalosporin class restriction significantly reduced nosocomial, plasmid-mediated, cephalosporin-resistant Klebsiella infection and colonization. This occurred at the price of increased imipenem resistance in P aeruginosa, which remained susceptible to other agents. Thus, an overall reduction in multiply-resistant pathogens was achieved within 1 year.
Rahal
J J
JJ
Department of Medicine, New York Hospital Medical Center of Queens and Cornell University Medical College, Flushing 11355, USA. cmurban%Queens@NYH.MED.Cornell.edu
Urban
C
C
Horn
D
D
Freeman
K
K
Segal-Maurer
S
S
Maurer
J
J
Mariano
N
N
Marks
S
S
Burns
J M
JM
Dominick
D
D
Lim
M
M
D000328:Adult; D018550:Cephalosporin Resistance; D002511:Cephalosporins / Q000627:therapeutic use*; D003428:Cross Infection / Q000453:epidemiology / Q000517:prevention & control*; D004352:Drug Resistance, Microbial; D017723:Drug Utilization Review / Q000706:statistics & numerical data; D019983:Guideline Adherence; D006746:Hospital Bed Capacity, 500 and over; D006764:Hospitals, Community; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D015994:Incidence; D017053:Infection Control; D007709:Klebsiella / Q000187:drug effects*; D007710:Klebsiella Infections / Q000453:epidemiology / Q000517:prevention & control*; D009519:New York City / Q000453:epidemiology; D011552:Pseudomonas Infections / Q000453:epidemiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013845:Thienamycins / Q000494:pharmacology
D002511:Cephalosporins; D013845:Thienamycins; D015378:Imipenem